Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Hematologic Malignancies
•
Medical Oncology
•
AML
•
Hematology
•
Benign Hematology
•
Eosinophilia
What etiologies would you consider for recurrent eosinophilia and thrombocytosis in an AML patient on Aza-Ven and in remission?
https://imgur.com/paTPuCE
AML did not have eosinophilia on presentation.
Related Questions
Do you prefer quizartinib over midostaurin with chemotherapy induction for FLT3-ITD mutated AML given the results of QUANTUM-FIRST and preclinical advantages over other FLT3 inhibitors?
What is your current approach to maintenance therapy in FLT3-mutant AML post allogeneic HCT?
With the recent approval of quizartinib, what is your preferred first-line FLT3 inhibitor in combination with chemotherapy for a fit AML patient with a FLT3-ITD mutation?
How would you manage a pre-menopausal woman with extranodal marginal zone lymphoma confined to the bladder wall?
How would you treat an otherwise healthy patient with newly diagnosed Stage IIA unfavorable classical Hodgkin lymphoma who has exceeded lifetime anthracycline dose (for other indications, not treated previously for Hodgkins)?
What is your treatment approach for HIV-associated large B-cell lymphoma (DLBCL) with secondary CNS involvement?
How would you treat an elderly newly diagnosed tDLBCL that has previously seen R-CHOP and Bendamustine-Obinutuzumab prior to the transformative event?
How should one approach advanced stage EBV+ DLBCL, NOS with concomitant HLH?
Following the BRUIN data in mantle cell lymphoma, will you routinely treat with pirtobrutinib following a covalent BTKi?
What is your approach to MRD testing in the frontline treatment of multiple myeloma?